Drug Approval | December 04, 2024
Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005%
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
The product will be marketed by Dr. Reddy's
The product will be manufactured at Lupin’s Somerset facility in the US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
This product will be manufactured at Lupin’s Nagpur facility in India
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Subscribe To Our Newsletter & Stay Updated
